文献速递慢性肾脏病肾血管病与高血压

PiT-2 对高磷饮食慢性肾脏病小鼠血管钙化的保护作用

PiT-2, a type III sodium-dependent phosphate transporter, protects against vascular calcification in mice with chronic kidney disease fed a high-phosphate diet.
PubMed 文献 · Kidney Int · 2018-07-21

本研究利用野生型和全身 PiT-2 杂合敲除小鼠,探讨 PiT-2 单倍剂量不足对尿毒症小鼠血管钙化的影响。结果显示,PiT-2 单倍剂量不足加剧了高磷饮食慢性肾脏病小鼠的血管钙化,且与血清矿物质标志物和肾功能无关。体外实验表明,PiT-2 通过调节血管平滑肌细胞的磷酸盐摄取和骨保护素水平来抑制磷酸盐诱导的钙化。

要点

  • PiT-2 单倍剂量不足加重慢性肾脏病高磷饮食小鼠的血管钙化。
  • PiT-2 缺失降低血管平滑肌细胞骨保护素水平并增加基质钙化。
  • 补充骨保护素可减轻 PiT-2 缺失血管平滑肌细胞的钙化。

核心结论

  • PiT-2 在血管平滑肌细胞中抑制磷酸盐诱导的血管钙化,可能成为慢性肾脏病患者的治疗靶点。

研究设计与样本

  • 使用野生型和全身 PiT-2 杂合敲除小鼠,建立慢性肾脏病并喂食高磷饮食。
  • 体外培养来自野生型和 PiT-2 杂合敲除小鼠的血管平滑肌细胞进行机制研究。

主要发现

  • PiT-2 单倍剂量不足增强慢性肾脏病高磷饮食小鼠的血管钙化。
  • 野生型与 PiT-2 杂合敲除组之间血清矿物质标志物和肾功能无差异。
  • PiT-2 杂合敲除小鼠尿毒症时股骨骨小梁骨密度降低。
  • PiT-2 杂合敲除小鼠血管平滑肌细胞的钠依赖性磷酸盐摄取减少。
  • PiT-2 缺失血管平滑肌细胞骨保护素水平降低、基质钙化增加,补充骨保护素可减轻钙化。

临床怎么用

  • PiT-2 可能作为慢性肾脏病血管钙化的潜在治疗靶点,但尚需临床研究验证。

局限性

  • 研究为动物和体外实验,结果不能直接推广至人类。
  • 未报告样本量、具体数值和统计细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PiT-2, a type III sodium-dependent phosphate transporter, is a causative gene for the brain arteriolar calcification in people with familial basal ganglion calcification. Here we examined the effect of PiT-2 haploinsufficiency on vascular calcification in uremic mice using wild-type and global PiT-2 heterozygous knockout mice. PiT-2 haploinsufficiency enhanced the development of vascular calcification in mice with chronic kidney disease fed a high-phosphate diet. No differences were observed in the serum mineral biomarkers and kidney function between the wild-type and PiT-2 heterozygous knockout groups. Micro computed tomography analyses of femurs showed that haploinsufficiency of PiT-2 decreased trabecular bone mineral density in uremia. In vitro, sodium-dependent phosphate uptake was decreased in cultured vascular smooth muscle cells isolated from PiT-2 heterozygous knockout mice compared with those from wild-type mice. PiT-2 haploinsufficiency increased phosphate-induced calcification of cultured vascular smooth muscle cells compared to the wild-type. Furthermore, compared to wild-type vascular smooth muscle cells, PiT-2 deficient vascular smooth muscle cells had lower osteoprotegerin levels and increased matrix calcification, which was attenuated by osteoprotegerin supplementation. Thus, PiT-2 in vascular smooth muscle cells protects against phosphate-induced vascular calcification and may be a therapeutic target in the chronic kidney disease population.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Yamada S, Leaf EM, Chia JJ, et al. PiT-2, a type III sodium-dependent phosphate transporter, protects against vascular calcification in mice with chronic kidney disease fed a high-phosphate diet. Kidney Int. 2018. PMID: 30041812. doi:10.1016/j.kint.2018.05.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。